Cardea Bio is the world's leading commercial manufacturer and developer of breakthrough graphene-based digital biosensor hardware, software, and molecular infrastructure. The Cardea infrastructure enables application of advanced biosensors to any biological system, making the technology the ideal conduit to enable the future Internet of Biology. Cardea's mission is to transform the life science and healthcare industries by collaborating with a consortium of Innovations Partners in order to create novel products and solutions for instant biological insights.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/22/19 | $7,800,000 | Series A-1 |
Alexandria Venture Investments Serra Ventures | undisclosed |
| 09/17/20 | $7,500,000 | Series A-2 |
Agilent Technologies Lifespan Investments Photon Fund Serra Ventures Table Mountain Capital Taihill Venture Tsingyuan Ventures | undisclosed |
